LD
CELG

Lipe & Dalton’s Celgene Corp CELG Stock Holding History

Lipe & Dalton’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-28,808
Closed -$3.33M – 69
2015
Q2 		$3.33M Sell
28,808
-470
-2% -$53.7K 2.39% 25
2015
Q1 		$3.38M Sell
29,278
-366
-1% -$43.7K 2.33% 26
2014
Q4 		$3.32M Sell
29,644
-350
-1% -$36.9K 2.22% 26
2014
Q3 		$2.84M Sell
29,994
-390
-1% -$35.2K 1.86% 26
2014
Q2 		$2.61M Sell
30,384
-70
-0.2% -$5.32K 1.64% 28
2014
Q1 		$2.19M Sell
30,454
-1,376
-4% -$109K 1.47% 28
2013
Q4 		$2.69M Sell
31,830
-40,766
-56% -$3.23M 1.84% 27
2013
Q3 		$5.59M Sell
72,596
-15,314
-17% -$1.07M 4.1% 4
2013
Q2 		$5.14M Buy
+87,910
New +$5.29M 4.27% 4

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lipe & Dalton's CELG Position: Q3 2015 in Review

Lipe & Dalton sold out of Celgene Corp (CELG) in Q3 2015, closing a stake of 28,808 shares — an estimated $3.33M sold.

Lipe & Dalton first reported a position in CELG in Q2 2013 and held it in 9 quarters. The position peaked at $5.59M in Q3 2013. 1,195 funds tracked by Wall St. Rank hold CELG as of Q3 2015.

  • Lipe & Dalton reported no remaining Celgene Corp position as of Q3 2015 after selling out during the quarter.
  • Lipe & Dalton sold 28,808 Celgene Corp shares in Q3 2015, an estimated $3.33M.
  • Lipe & Dalton first reported a position in Celgene Corp in Q2 2013 and held it in 9 quarters.
  • Lipe & Dalton's Celgene Corp position peaked at $5.59M in Q3 2013.
  • 1,195 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2015.

Based on Lipe & Dalton's 13F filing for Q3 2015, filed 13 Nov 2015.